Stephanie B. Tsai, MD
Hematology, Hematology & Oncology, Internal Medicine, Medical Oncology
Provider Groups
Loyola Medicine Physician
Loyola Physician Partners
Primary Contact
(888)584-7888
Services & Specialties
Areas of Specialization
- Hematology
- Hematology & Oncology
- Internal Medicine
- Medical Oncology
Clinical Interests
Conditions Treated
- leukemia
- non hodgkin lymphoma
- thrombocytopenia
- acute lymphoblastic leukemia (all)
- acute myelogenous leukemia (aml)
- bone marrow disorders
- chronic lymphocytic leukemia
- multiple myeloma
- myelodysplastic syndrome
Locations & Contact
Primary Location
Loyola University Medical Center
2160 S First Ave
Maywood
, IL 60153
Marjorie Weinberg Cancer Center
675 W N Ave
Melrose Park
, IL 60160
Michiana Hematology Oncology PC
5340 Holy Cross Pkwy
Mishawaka
, IN 46545
About
Treating hematology disorders, with a focus on leukemias and hematopoietic stem cell transplantation (HCY), including all phases of treatment. Emphasizes provision of comprehensive and compassionate care to patients and their support, while applying the latest advances, therapies, and available knowledge. Research efforts concentrate on leukemias, as a member of national working groups and leader for the Loyola Leukemia Research program, as well as in HCT.
Academic Title
Associate Professor
Leadership Title
Unit Medical Director, Division of Hematology/Oncology
Leader, Loyola Leukemia Research Program
Quality Medical Director, Hematology/Oncology/BMT
Ages Seen
Additional Resources
Education & Certifications
Education
Education:
Boston University School of Medicine
(2009)
Residency:
Boston Medical Center
(2012)
Fellowship:
The University of Chicago Hospitals and Health System
(2015)
Board Certifications
Hematology, Hematology, American Board of Internal Medicine Subspecialty (2017)
Medical Oncology, Medical Oncology, American Board of Internal Medicine Subspecialty (2015)
Internal Medicine, Internal Medicine, American Board of (2012)
Provider Groups
Loyola Medicine Physician
Loyola Physician Partners
Publications
- Impact of Prior Inotuzumab Ozogamicin Treatment on Brexucabtagene Autoleucel outcomes in Adults with B-cell ALL. Aldoss, I.; Roloff, G. W.; Faramand, R. G.; Kopmar, N. E.; Lin, C.; Advani, A. S.; Dekker, S. E.; Gupta, V. K.; O'Connor, T. E.; Jeyakumar, N.; Muhsen, I. N.; Valtis, Y. K.; Zhang, A.; Miller, K.; Sutherland, K. C.; Dykes, K. C.; Ahmed, M.; Chen, E. C.; Zambrano, H.; Bradshaw, D.; Mercadal, S.; Schwartz, M. S.; Tracy, S. I.; Dholaria, B.; Kubiak, M. J.; Mukherjee, A.; Majhail, N. S.; Battiwalla, M.; Mountjoy, L.; Malik, S. A.; Mathews, J.; Shaughnessy, P. J.; Logan, A.; Ladha, A.; Stefan, M.; Guzowski, C.; Hoeg, R. T.; Hilal, T.; Moore, J.; Connor, M.; O'Dwyer, K. M.; Hill, L. C.; Tsai, S. B.; Sasine, J. P.; Solh, M. M.; Lee, C. J.; Kota, V.; Koura, D.; Veeraputhiran, M.; Blunk, B.; Oliai, C.; Leonard, J. T.; Frey, N. V.; Park, J. H.; Luskin, M. R.; Bachanova, V.; Galal, A.; Bishop, M. R.; Stock, W.; Cassaday, R. D.; Pullarkat, V. A.; Shah, B. D.; Muffly, L.; Blood advances
- Air pollutant impact on disease characteristics and outcomes in patients with acute myeloid leukemia. Palmer, A.; Rauscher, G.; Abraham, I.; Burkart, M.; Dave, A.; Raptis, N.; Aleem, A.; Gannamani, V.; Erra, A.; Monick, S.; Galvez, C.; Shah, S.; Rahmani Youshanlouei, H.; Larson, M. L.; Zia, M.; Tsai, S. B.; Altman, J. K.; Stock, W.; Khan, I.; Patel, A. A.; Blood advances
- Busulfan, melphalan and carfilzomib high-dose chemotherapy and autologous haematopoietic stem cell transplantation in multiple myeloma. Hagen, P.; Norton, J.; Tsai, S.; Campo, L.; Lee, M.; Gomez, K.; Stiff, P.; British journal of haematology
- Structural racism is a mediator of disparities in acute myeloid leukemia outcomes. Abraham, I. E.; Rauscher, G. H.; Patel, A. A.; Pearse, W. B.; Rajakumar, P.; Burkart, M.; Aleem, A.; Dave, A.; Bharadwaj, S.; Paydary, K.; Acevedo-Mendez, M.; Goparaju, K.; Gomez, R.; Carlson, K.; Tsai, S. B.; Quigley, J. G.; Galvin, J. P.; Zia, M.; Larson, M. L.; Berg, S.; Stock, W.; Altman, J. K.; Khan, I.; Blood
- Low mean post-transplantation tacrolimus levels in weeks 2-3 correlate with acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation from related and unrelated donors. Hagen, P. A.; Adams, W.; Smith, S.; Tsai, S.; Stiff, P.; Bone marrow transplantation
- Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults. Tsai, S. B.; Rhodes, J.; Liu, H.; Shore, T.; Bishop, M.; Cushing, M. M.; Gergis, U.; Godley, L.; Kline, J.; Larson, R. A.; Mayer, S.; Odenike, O.; Stock, W.; Wickrema, A.; van Besien, K.; Artz, A. S.; Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
- Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning. Tsai, S. B.; Liu, H.; Shore, T.; Fan, Y.; Bishop, M.; Cushing, M. M.; Gergis, U.; Godley, L.; Kline, J.; Larson, R. A.; Martinez, G.; Mayer, S.; Odenike, O.; Stock, W.; Wickrema, A.; van Besien, K.; Artz, A. S.; Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation